Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Twist Bioscience Corporation - Common Stock (NQ: TWST )

47.76 +1.06 (+2.27%)
Streaming Delayed Price Updated: 3:55 PM EST, Feb 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Twist Bioscience Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Cathie Wood's Ark Invest Loads Up On Iridium, Twist Bioscience, Offloads Roku: Here Are Key Ark Trades This Friday
Cathie Wood-led Ark Invest made trades involving IRDM, TWST, PD, BEAM, ROKU, and IBTA. 
Via Benzinga
Cathie Wood Dumps $16 Million Worth Of Palantir Stock After Record Highs
On Monday, February 10, 2025, the Cathie Wood-led Ark Invest sold nearly $16 million worth of Palantir shares amid a spike in the share price of the company. 
Via Benzinga
Cathie Wood's Ark Invest Bets Big On Amazon, Roblox And Illumina While Trimming Palantir Stake After Alex Karp-Led Company Touched An All-Time High On Thursday
Ark Invest made significant trades on Friday, including buying Amazon and Roblox stock and selling Palantir stock. Other key trades were also made. 
Via Benzinga
Forecasting The Future: 6 Analyst Projections For Twist Bioscience
Via Benzinga
Top Wall Street Forecasters Revamp Twist Bioscience Price Expectations Ahead Of Q4 Earnings
Via Benzinga
Twist Bioscience Earnings Preview
Via Benzinga
Deep Dive Into Twist Bioscience Stock: Analyst Perspectives (5 Ratings)
Via Benzinga
Earnings Scheduled For February 3, 2025
Via Benzinga
Cathie Wood Sees Tesla As 'Largest AI Project On Earth' — Here's Why She's Not Worried About Tech Investments
Cathie Wood, founder and CEO of ARK Investment Management LLC, defended the future of artificial intelligence investments while highlighting Tesla Inc. as a cornerstone of technological innovation... 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared?
Cathie Wood, CEO of ARK Invest, is doubling down on biologics, seeing unprecedented potential at the intersection of artificial intelligence, genetic sequencing, and gene editing technologies. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Evaluating Twist Bioscience: Insights From 5 Financial Analysts
Via Benzinga
Key Takeaways From Twist Bioscience Analyst Ratings
Via Benzinga
Expert Outlook: Twist Bioscience Through The Eyes Of 6 Analysts
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Crude Oil Rises Sharply; US Homebuilder Sentiment Surges In November
Via Benzinga
Exposures Fossil Fuels
Twist Bioscience's Q4 Earnings And Q1 Guidance Surpass Expectations, Stock Jumps
Twist Bioscience's Q4 results topped estimates, with revenue up 27% YoY. Fiscal 2025 guidance includes revenue growth and a targeted gross margin of 48%. 
Via Benzinga
Twist Bioscience Posts Upbeat Results, Joins Tesla, Amylyx Pharmaceuticals, Regenxbio And Other Big Stocks Moving Higher On Monday
Via Benzinga
Earnings Scheduled For November 18, 2024
Via Benzinga
Cathie Wood's Ark Innovation, Genomic ETFs Celebrate 10 Years: How Annual Returns Stack Up Against S&P 500
The Ark Innovation and Ark Genomic ETFs turn ten years old. A look at the annual returns and current top holdings. 
Via Benzinga
Topics ETFs Stocks
Exposures US Equities
Coeur Mining, Medical Properties Trust And RH Are Among Top 7 Mid Cap Stock Gainers Last Week (Sep 8-Sep 14): Are The Others In Your Portfolio?
7 mid-cap stocks with impressive gains last week: CDE, MPW, NGD, RH, AUR, TWST, ALHC. Positive news and financial results drove the surge. 
Via Benzinga
3 Healthcare AI Stocks Positioned for Potential Breakthroughs
The Japanese central bank’s decision creates a prime opportunity. Take advantage of it with these three healthcare AI stocks. 
Via InvestorPlace
Topics Artificial Intelligence Economy
Exposures Artificial Intelligence Interest Rates
Sotera Health Posts Upbeat Results, Joins Thoughtworks, Sonic Automotive And Other Big Stocks Moving Higher On Monday
Via Benzinga
The 3 Best Med Tech Stocks to Buy Now
Med tech firms are tremendously improving healthcare and making a great deal of money. Here are the three best med tech stocks to buy now. 
Via InvestorPlace
Twist Bioscience Beats Q3 Earnings Forecast, Plans To Achieve 50% Gross Margin By Fiscal Year 2025
Twist Bioscience reported a Q3 adjusted EPS loss of $(0.70), surpassing the $(0.77) consensus. With a net loss of $85.6 million and sales at $81.5 million, Twist Bioscience saw a 27.8% year-over-year... 
Via Benzinga
Biotech Bull Market Is Intact But SMIDs Are Too Volatile
It was another wild week for the market as it had to contend with a lot of news. 
Via Talk Markets
Cathie Wood Touts Palantir, Coinbase And Roku As ARK's Flagship Fund Shifts Focus From Mag 6 Amid 'Whiff' Of Lower Interest Rates
In a recent letter to investors, Cathie Wood, the CEO of ARK Invest, highlighted the potential of the company's flagship fund, ARK Innovation ETF, despite its recent underperformance. 
Via Benzinga
Topics ETFs
Cathie Wood's Ark Invest Sells Tesla Shares Worth $14.5M Amid Rally Driven By Q2 Delivery Numbers, Picks Up Palantir Shares Again Today
Via Benzinga
Novavax And Agios Pharmaceuticals Were Among The 10 Biggest Mid-Cap Gainers Last Week (June 1-June 7): Are These In Your Portfolio?
Mid-cap stocks saw significant gains last week, with top performers like AGIO, VRNT, and NVAX, causing analysts to raise their forecasts. 
Via Benzinga
Ollie's Bargain Outlet Posts Upbeat Earnings, Joins Verint Systems, Guidewire Software And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
This Old Dominion Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.